Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2018-04-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于投资受让众惠保险社初始运营资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhuhai Jianfan Biotechnology Co., Ltd. regarding its investment to acquire initial operating funds loan claims of Zhonghui Insurance Society. It details the transaction parties, terms, payment arrangements, risks, and approvals needed. The content focuses on a capital investment transaction and related financing details, including loan transfer agreements and regulatory approval requirements. There is no financial statement or comprehensive financial report included, nor is it a report publication announcement or certification. The document is a formal announcement about a financing transaction and capital structure change. Therefore, it fits best under the category 'Capital/Financing Update' (CAP). The document length is 4081 characters, which is consistent with an announcement rather than a full report.
2018-04-24 Chinese
关于2016年限制性股票激励计划首次授予股票第一个解除限售期股份上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement from Zhuhai Jianfan Biotechnology Co., Ltd. regarding the unlocking and listing of restricted shares from the 2016 restricted stock incentive plan. It includes specifics about the number of shares unlocked, the conditions met for unlocking, the dates, the number of incentive recipients, and the board and supervisory approvals. The document is not a full financial report but a regulatory announcement about share unlocking and listing related to a stock incentive plan. It does not contain financial statements or earnings data, nor is it a proxy or voting result announcement. It is a formal disclosure about share capital changes related to restricted stock unlocking and listing. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement but a substantive disclosure about capital changes.
2018-04-23 Chinese
关于与众惠保险社签订战略合作协议书的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhuhai Jianfan Biological Technology Co., Ltd. about signing a strategic cooperation agreement with Zhonghui Insurance Society. It details the nature of the agreement, the parties involved, the cooperation scope, and the potential impact on the company. The document explicitly states that the agreement is a framework for future cooperation and does not involve specific transaction amounts or immediate financial impact. There are no financial statements, quarterly or annual results, or audit information included. The document is relatively short (2970 characters) and serves as a formal announcement of a strategic partnership agreement rather than a financial report or detailed investor presentation. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance or officer certification. The best fitting category is Capital/Financing Update (CAP) because it relates to a strategic cooperation agreement that includes the company's intention to invest in the insurance society, which is a capital-related update. Confidence is high given the clear description and nature of the document.
2018-04-18 Chinese
2018年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2018 First Quarter Report" of 珠海健帆生物科技股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data including income statement, balance sheet, cash flow statement, financial metrics, risk factors, shareholder information, and management discussion of business activities during the quarter. The presence of actual financial statements and substantive financial analysis confirms it is a comprehensive interim report rather than a brief announcement or certification. The document length is substantial (15,000 characters), and it includes detailed financial tables and narrative sections typical of an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2018
2018-04-16 Chinese
2018年第一季度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (447 characters) regarding the disclosure of the company's 2018 first quarter report. It states that the quarterly report has been approved by the board and is available on the official disclosure website. The document does not contain the actual financial data or detailed report content but serves as a notice to investors to review the full report elsewhere. According to the 'MENU VS MEAL' rule, such a brief announcement that points to the report's publication without including the report itself should be classified as a Report Publication Announcement (RPA).
2018-04-16 Chinese
2018年第一季度业绩预增公告
Earnings Release Classification · 95% confidence The document is a quarterly earnings forecast announcement for the first quarter of 2018 by Zhuhai Jianfan Biotechnology Co., Ltd. It provides estimated net profit growth percentages and mentions that the forecast has not been audited. It explicitly states that detailed financial data will be disclosed in the company's first quarter report. The document is short (698 characters) and serves as a preliminary earnings guidance rather than a full financial report. According to the rules, such earnings forecasts or initial announcements of quarterly results are classified as Earnings Release (ER). Q1 2018
2018-04-09 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.